Leila A Kutteh

C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.

Peter A Kaufman, Lyndsay N Harris, James N Ingle, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Greg Yothers, Peter A Kaufman, Norman Wolmark, 2005, The New England journal of medicine.